#Exebacase is a novel direct lytic agent (#lysin) under clinical development – a purified protein produced from a gene originally cloned from #bacteriophage such that the final product is devoid of phage material. Exebacase has activity against all staph species, with potent…

Frontiers | Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection Exebacase, a recombinantly produced lysin has recently (i) reported proof-of-concept data from a phase II study in S. aureus bacteremia and (ii) demonstrated...

Arthroscopie lavage @CrioacLyon @CHUdeLyon avec administration locale de CF-301 (#phage #Lysin appelé #Exebacase @ContraFectCorp 🇺🇸) chez 4 patients âgés atteints d'une infection récidivante du genou à S. epidermidis multiresistant

frontiersin.org/article/10.338…

Frontiers | Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection Exebacase, a recombinantly produced lysin has recently (i) reported proof-of-concept data from a phase II study in S. aureus bacteremia and (ii) demonstrated...

Arthroscopic “Debridement and Implant Retention” with local administration of #Exebacase (#phage #Lysin called CF-301 from @ContraFectCorp) @CrioacLyon @CHUdeLyon in 4 elderly patients with relapsing multiresistant S. epidermidis prosthetic knee infection

frontiersin.org/article/10.338…

Great interview of V. Fischetti @microbephage from Rockefeller University 🇺🇸 in this podcast about the #bacteriophage lysin CF-301 #exebacase: ´The First-Ever Antibiotic Alternative to Move Into Phase 3 Clinical Trials’!

futuretechhealth.com/podcasts/the-f…